Why Amgen’s positive biosimilar news isn’t as good as it seems By: MarketWatch July 13, 2016 at 12:39 PM EDT FDA committee’s unanimous vote belies the complexity of getting these new drugs to market. Read More >> Related Stocks: AbbVie Amgen Baxter International Coherus Bio Momenta Pharma Pfizer Standard & Poors 500